Basic Information
RNALocate ID: | RLID:11001454 |
RNA Symbol: | hsa-miR-199b-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-199b |
RNA ID: | miRBase:MIMAT0000263 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20615901 |
Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
Method: | Microarray|qRT-PCR|RT-PCR |
Description: | Exosomal miRNAs as potential biomarkers and therapeutic targets. Data are collected from Table 1. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11001455 | Exosome | B cell line (Raji)|Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001456 | Exosome | Brain tissue | 23382797 |
RLID:11001457 | Exosome | Plasma | 23663360 |
RLID:11001458 | Exosome | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells | 25242326 |
RLID:11001459 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11001460 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID-D:11000324 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001168 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-199b-5p | Splenic marginal zone lymphoma | MNDR-E-MI-25054 |
MNDR | hsa-miR-199b-5p | Oral squamous cell carcinoma | MNDR-E-MI-25055 |
MNDR | hsa-miR-199b-5p | Large cell neuroendocrine cancer | MNDR-E-MI-25056 |
MNDR | hsa-miR-199b-5p | Medulloblastoma | MNDR-E-MI-25057 |
MNDR | hsa-miR-199b-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25058 |
MNDR | hsa-miR-199b-5p | Lymphoma | MNDR-E-MI-25059 |
MNDR | hsa-miR-199b-5p | Lymphoma non-hodgkin | MNDR-E-MI-25060 |
MNDR | hsa-miR-199b-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-25061 |
MNDR | hsa-miR-199b-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-25062 |
MNDR | hsa-miR-199b-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-25063 |
MNDR | hsa-miR-199b-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-25064 |
MNDR | hsa-miR-199b-5p | Her2-receptor positive breast cancer | MNDR-E-MI-25065 |
MNDR | hsa-miR-199b-5p | Niemann-pick disease type c | MNDR-E-MI-25066 |
MNDR | hsa-miR-199b-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-25067 |
MNDR | hsa-miR-199b-5p | Dermatomyositis | MNDR-E-MI-25068 |
MNDR | hsa-miR-199b-5p | Prostate cancer | MNDR-E-MI-25069 |
MNDR | hsa-miR-199b-5p | Gastric cancer | MNDR-E-MI-25070 |
MNDR | hsa-miR-199b-5p | Gastric lymphoma | MNDR-E-MI-25071 |
MNDR | hsa-miR-199b-5p | Alzheimer disease | MNDR-E-MI-25072 |
MNDR | hsa-miR-199b-5p | Intracranial aneurysm | MNDR-E-MI-25073 |
MNDR | hsa-miR-199b-5p | Bladder cancer | MNDR-E-MI-25074 |
MNDR | hsa-miR-199b-5p | Dysautonomia familial | MNDR-E-MI-25075 |
MNDR | hsa-miR-199b-5p | Muscular dystrophy duchenne | MNDR-E-MI-25076 |
MNDR | hsa-miR-199b-5p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-25077 |
MNDR | hsa-miR-199b-5p | Head and neck cancer | MNDR-E-MI-25078 |
MNDR | hsa-miR-199b-5p | Leukemia | MNDR-E-MI-25079 |
MNDR | hsa-miR-199b-5p | Ataxia telangiectasia | MNDR-E-MI-25080 |
MNDR | hsa-miR-199b-5p | Cardiovascular disease | MNDR-E-MI-25081 |
MNDR | hsa-miR-199b-5p | Lung cancer | MNDR-E-MI-25082 |
MNDR | hsa-miR-199b-5p | Parkinson disease | MNDR-E-MI-25083 |
MNDR | hsa-miR-199b-5p | Niemann-pick disease | MNDR-E-MI-25084 |
MNDR | hsa-miR-199b-5p | Breast cancer | MNDR-E-MI-25085 |
MNDR | hsa-miR-199b-5p | Neuroendocrine neoplasia | MNDR-E-MI-25086 |
MNDR | hsa-miR-199b-5p | Thyroid cancer | MNDR-E-MI-25087 |
MNDR | hsa-miR-199b-5p | Pituitary neoplasms | MNDR-E-MI-25088 |
MNDR | hsa-miR-199b-5p | Pancreatic cancer | MNDR-E-MI-25089 |
MNDR | hsa-miR-199b-5p | Melanoma | MNDR-E-MI-25090 |
MNDR | hsa-miR-199b-5p | Rectum adenocarcinoma | MNDR-E-MI-25091 |
MNDR | hsa-miR-199b-5p | Nephroblastoma | MNDR-E-MI-25092 |
MNDR | hsa-miR-199b-5p | Colon cancer | MNDR-E-MI-25093 |
MNDR | hsa-miR-199b-5p | Colon adenocarcinoma | MNDR-E-MI-25094 |
MNDR | hsa-miR-199b-5p | Ovarian cancer | MNDR-E-MI-25095 |
MNDR | hsa-miR-199b-5p | Prostate adenocarcinoma | MNDR-E-MI-25096 |
MNDR | hsa-miR-199b-5p | Carcinoma ductal breast | MNDR-E-MI-25097 |
MNDR | hsa-miR-199b-5p | Glioblastoma | MNDR-E-MI-25098 |
MNDR | hsa-miR-199b-5p | Astrocytoma | MNDR-E-MI-25099 |
MNDR | hsa-miR-199b-5p | Glioma | MNDR-E-MI-25100 |
MNDR | hsa-miR-199b-5p | Nemaline myopathy | MNDR-E-MI-25101 |
MNDR | hsa-miR-199b-5p | Temporal lobe epilepsy | MNDR-E-MI-25102 |
MNDR | hsa-miR-199b-5p | Osteosarcoma | MNDR-E-MI-25103 |
MNDR | hsa-miR-199b-5p | Mesenchymal cancer | MNDR-E-MI-25104 |
MNDR | hsa-miR-199b-5p | Breast carcinoma | MNDR-E-MI-25105 |
MNDR | hsa-miR-199b-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-25106 |
MNDR | hsa-miR-199b-5p | Liver cancer | MNDR-E-MI-25107 |
MNDR | hsa-miR-199b-5p | Choriocarcinoma | MNDR-E-MI-25108 |
MNDR | hsa-miR-199b-5p | Uterus cancer | MNDR-E-MI-25109 |
MNDR | hsa-miR-199b-5p | Gastric adenocarcinoma | MNDR-E-MI-25110 |
MNDR | hsa-miR-199b-5p | Cervical squamous cell carcinoma | MNDR-E-MI-25111 |
MNDR | hsa-miR-199b-5p | Pituitary adenoma | MNDR-E-MI-25112 |
MNDR | hsa-miR-199b-5p | Lung squamous cell carcinoma | MNDR-E-MI-25113 |
MNDR | hsa-miR-199b-5p | Lung adenocarcinoma | MNDR-E-MI-25114 |
MNDR | hsa-miR-199b-5p | Adrenocortical carcinoma | MNDR-E-MI-25115 |
MNDR | hsa-miR-199b-5p | Thyroid carcinoma | MNDR-E-MI-25116 |
MNDR | hsa-miR-199b-5p | Papillary thyroid carcinoma | MNDR-E-MI-25117 |
MNDR | hsa-miR-199b-5p | Bladder urothelial carcinoma | MNDR-E-MI-25118 |
MNDR | hsa-miR-199b-5p | Pancreatic adenocarcinoma | MNDR-E-MI-25119 |
MNDR | hsa-miR-199b-5p | Cervical cancer | MNDR-E-MI-25120 |
MNDR | hsa-miR-199b-5p | Carcinoma renal cell | MNDR-E-MI-25121 |
MNDR | hsa-miR-199b-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25122 |
MNDR | hsa-miR-199b-5p | Clear cell renal cell carcinoma | MNDR-E-MI-25123 |
MNDR | hsa-miR-199b-5p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-25124 |
MNDR | hsa-miR-199b-5p | Cholangiocarcinoma | MNDR-E-MI-25125 |
MNDR | hsa-miR-199b-5p | Esophageal cancer | MNDR-E-MI-25126 |
MNDR | hsa-miR-199b-5p | Lung small cell carcinoma | MNDR-E-MI-25127 |
MNDR | hsa-miR-199b-5p | Gastric carcinoma | MNDR-E-MI-25128 |
MNDR | hsa-miR-199b-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-25129 |
MNDR | hsa-miR-199b-5p | Adenoma | MNDR-E-MI-25130 |
MNDR | hsa-miR-199b-5p | Breast invasive carcinoma | MNDR-E-MI-25131 |
MNDR | hsa-miR-199b-5p | Hepatocellular carcinoma | MNDR-E-MI-25132 |
MNDR | hsa-miR-199b-5p | B-cell lymphoma | MNDR-E-MI-25133 |
MNDR | hsa-miR-199b-5p | Rheumatoid arthritis | MNDR-E-MI-25134 |
MNDR | hsa-miR-199b-5p | T-cell leukemia | MNDR-E-MI-25135 |
MNDR | hsa-miR-199b-5p | Hodgkin lymphoma | MNDR-E-MI-25136 |
MNDR | hsa-miR-199b-5p | Burkitt lymphoma | MNDR-E-MI-25137 |
MNDR | hsa-miR-199b-5p | Tonsil cancer | MNDR-E-MI-25138 |
MNDR | hsa-miR-199b-5p | Acute myelocytic leukemia | MNDR-E-MI-25139 |
MNDR | hsa-miR-199b-5p | Colorectal cancer | MNDR-E-MI-25140 |
MNDR | hsa-miR-199b-5p | Nasopharynx carcinoma | MNDR-E-MI-25141 |
MNDR | hsa-miR-199b-5p | Diabetic nephropathies | MNDR-E-MI-25142 |
MNDR | hsa-miR-199b-5p | Ependymoma | MNDR-E-MI-25143 |
MNDR | hsa-miR-199b-5p | Cardiomegaly | MNDR-E-MI-25144 |
MNDR | hsa-miR-199b-5p | Nasopharyngeal cancer | MNDR-E-MI-25145 |
MNDR | hsa-miR-199b-5p | Prostatic neoplasms | MNDR-E-MI-25146 |
MNDR | hsa-miR-199b-5p | Polymyositis | MNDR-E-MI-25147 |
MNDR | hsa-miR-199b-5p | Pancreatitis chronic | MNDR-E-MI-25148 |
MNDR | hsa-miR-199b-5p | Breast cancer her3+ negative | MNDR-E-MI-25149 |
MNDR | hsa-miR-199b-5p | Tubulovillous adenoma | MNDR-E-MI-25150 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | APP | Homo sapiens | RR00091806 |
TOP